Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/33558
DC FieldValueLanguage
dc.contributor.authorPetar Avramovskien_US
dc.contributor.authorEmilija Pariskoen_US
dc.contributor.authorMaja Avramovskaen_US
dc.contributor.authorPece Stefanovskien_US
dc.contributor.authorZorica Nikleskien_US
dc.contributor.authorLiljana Todorovskaen_US
dc.contributor.authorBiljana Talevaen_US
dc.contributor.authorSvetlana Stefanovskaen_US
dc.contributor.authorVesna Siklovskaen_US
dc.contributor.authorIlija Kelepurovskien_US
dc.contributor.authorKosta Sotiroskien_US
dc.contributor.authorDejan Zdraveskien_US
dc.date.accessioned2025-05-15T12:54:50Z-
dc.date.available2025-05-15T12:54:50Z-
dc.date.issued2025-04-11-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/33558-
dc.description.abstractBackground: L-Ornithine L-Aspartate (LOLA), known commercially as Hepa-Merz, is widely used in the treatment of hepatic encephalopathy (HE) due to its ability to facilitate ammonia clearance via both urea and glutamine pathways. In addition to its established role in HE, emerging evidence suggests LOLA may aid liver regeneration, support mitochondrial function, and reduce oxidative stress. This study investigates LOLA's potential impact on cognitive performance in individuals with minimal hepatic encephalopathy (MHE), utilizing the Stroop Test as a neuropsychological evaluation tool and correlating findings with serum ammonia concentrations. Methods: Sixty-five patients diagnosed with MHE underwent cognitive evaluation before and after administration of LOLA. Ammonia levels were quantified both pre- and post-intervention. The Stroop Test, including Stroop Word (SW), Stroop Color (SC), Stroop Color-Word (SCW), and the Total Stroop Test (TST), was used to assess changes in cognitive speed and accuracy. Data were analyzed using unpaired t-tests to evaluate the significance of observed changes. Results: Post-treatment results showed a significant decrease in blood ammonia levels (from 123.2 ± 27.1 µmol/L to 112.7 ± 24.1 µmol/L, p < 0.05). All Stroop Test components demonstrated marked improvement, with faster TST indicating better cognitive processing. Moreover, patients with initially elevated ammonia levels tended to perform worse on cognitive testing, reinforcing the link between hyperammonemia and cognitive dysfunction. Conclusion: Hepa-Merz demonstrates efficacy in reducing systemic ammonia and enhancing cognitive function in MHE patients. The Stroop Test proves to be a sensitive and practical measure for detecting neurocognitive changes and treatment effects. These findings support further exploration of LOLA’s (Hepa-Merz) benefits beyond traditional HE management, particularly in preserving or improving brain function.en_US
dc.language.isoenen_US
dc.publisherECRONICON open acesssen_US
dc.relation.ispartofEC Pulmonology and Respiratory Medicineen_US
dc.relation.ispartofseries;Volume 14 Issue 5 - 2025-
dc.subjectL-Ornithine L-Aspartateen_US
dc.subjectHepatic Encephalopathyen_US
dc.subjectAmmonia Detoxificationen_US
dc.subjectCognitive Functionen_US
dc.subjectStroop Testen_US
dc.subjectMinimal Hepatic Encephalopathyen_US
dc.subjectHepa-Merzen_US
dc.titleCognitive Function Assessment Using the Stroop Test: Exploring the Broader Therapeutic Potential of L-Ornithine L-Aspartate (LOLA, Hepa-Merz), a Hepatic Encephalopathy Medicationen_US
dc.typeArticleen_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File SizeFormat 
ECPRM-14-01065.pdf381.82 kBAdobe PDFView/Open
Прикажи едноставен запис

Google ScholarTM

Проверете


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.